Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 12/20 | 0.63 |
| ▸ | ABL1 | P00519 | 3/20 | 0.63 |
| ▸ | BCR | P11274 | 3/20 | 0.63 |
| ▸ | ESYT2 | A0FGR8 | 2/20 | 0.63 |
| ▸ | NBAS | A2RRP1 | 2/20 | 0.63 |
| ▸ | CNOT1 | A5YKK6 | 2/20 | 0.63 |
| ▸ | TBKBP1 | A7MCY6 | 2/20 | 0.63 |
| ▸ | AGPS | O00116 | 2/20 | 0.63 |
| ▸ | MYO1F | O00160 | 2/20 | 0.63 |
| ▸ | SNAP23 | O00161 | 2/20 | 0.63 |
| ▸ | AP3B1 | O00203 | 2/20 | 0.63 |
| ▸ | PSMD12 | O00232 | 2/20 | 0.63 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.63 |
| ▸ | PGRMC1 | O00264 | 2/20 | 0.63 |
| ▸ | CLIC1 | O00299 | 2/20 | 0.63 |
| ▸ | CDC7 | O00311 | 2/20 | 0.63 |
| ▸ | IPO5 | O00410 | 2/20 | 0.63 |
| ▸ | PLK4 | O00444 | 2/20 | 0.63 |
| ▸ | COXFA4 | O00483 | 2/20 | 0.63 |
| ▸ | NOP56 | O00567 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22025337 | 0.94 | DDR1 (0.72) | BRAFABL1BCRESYT2NBAS | |
| SCHEMBL22025470 | 0.92 | BRAF (0.60) | BRAFABL1BCRESYT2NBAS | |
| SCHEMBL22024717 | 0.88 | BRAF (0.72) | BRAFABL1BCRESYT2NBAS | |
| SCHEMBL22024755 | 0.87 | PIKFYVE (0.73) | BRAFABL1BCRESYT2NBAS | |
| SCHEMBL22025477 | 0.85 | BRAF (0.60) | BRAFABL1BCRESYT2NBAS | |
| SCHEMBL22024572 | 0.84 | BRAF (0.67) | BRAFABL1BCRESYT2NBAS | |
| SCHEMBL22024570 | 0.84 | PIKFYVE (0.77) | BRAFABL1BCRESYT2NBAS | |
| SCHEMBL24532075 | 0.84 | BRAF (0.89) | BRAFABL1BCRESYT2NBAS | |
| SCHEMBL4697866 | 0.84 | BRAF (0.89) | BRAFABL1BCRESYT2NBAS | |
| SCHEMBL21943601 | 0.83 | KDR (0.58) | BRAFABL1BCRESYT2NBAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352354-B2 | Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | XIAMEN UNIVERSITY (CN) | 2022-06-07 | — | — | US | disclosed |
| EP-3663293-A1 | SUBSTITUTED PENTA- AND HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | Xiamen University (CN) | 2020-06-10 | — | — | EP | disclosed |
| US-20200165246-A1 | SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | XIAMEN UNIVERSITY (CN) | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352354-B2 | Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | PIKFYVE, PIK3CA, PIK3C2A | BRAF 65/4885ABL1 1429/4885BCR 1416/4885 |
| US-20200165246-A1 | SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | PIKFYVE, PIK3CA, PIK3C2A | BRAF 65/4885ABL1 1429/4885BCR 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.